Month: September 2021

Gevo Acquires Butamax Patent Estate

Posted on by Admin


Gevo Acquires Butamax Patent Estate

 

ENGLEWOOD, Colo., Sept. 23, 2021 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) is pleased to announce that it has entered into an asset purchase agreement, dated September 21, 2021, with Butamax Advanced Biofuels LLC (“Butamax”) and its affiliate, Danisco US Inc., to acquire certain patents, leaving Gevo as the only entity with full rights to sublicense the entire Gevo/Butamax isobutanol and isobutanol derivatives patent estate in the fields of fuels, isooctane, industrial chemicals, isobutylene, oligomerized isobutylene, and para-xylene (the “Asset Purchase Agreement”). The transaction contemplated by the Asset Purchase Agreement closed on September 21, 2021 and is subject to certain existing rights and obligations.

The Asset Purchase Agreement provides Gevo with direct ownership and management over the entire known isobutanol patent portfolio of Butamax. Butamax previously entered into a patent cross-license agreement with Gevo effective as of August 22, 2015 (the “Patent-Cross License Agreement”). The Asset Purchase Agreement terminates the Patent-Cross License Agreement in most respects.

In 2020, Gevo commissioned Peak Value IP, LLC to complete a valuation of its worldwide intellectual property that could be licensed and monetized by Gevo. This valuation included the Butamax-owned patents available for Gevo to use and the Gevo-owned patents, patent applications, trade secrets, and know-how (collectively, the “IP”). Peak Value’s analysis yielded an indicative investment valuation of approximately $412 million for the full scope of the Gevo IP portfolio. The Butamax patent estate acquisition is expected to increase Gevo’s intellectual property value, now that Gevo owns the Butamax patents.

“Gevo is ‘all in’ on IBA-related technologies. We are finding strong commercial demand for our products. So, it simply makes sense for us to own the patent estate. In addition, it gives us more flexibility in adding to the combined patent estate and eliminates the complexity for out-licensing that existed under the Patent Cross-License Agreement,” commented Dr. Chris Ryan, President and Chief Operating Officer of Gevo.

For more information and details about the Asset Purchase Agreement and the termination of the Patent Cross-License Agreement, please see the Current Report on Form 8-K that Gevo filed with the U.S. Securities and Exchange Commission on September 23, 2021.

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full life cycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their life cycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low-carbon products such as gasoline components, jet fuel and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business. Gevo believes that the Argonne National Laboratory GREET model is the best available standard of scientific-based measurement for life cycle inventory or LCI. Learn more at Gevo’s website: www.gevo.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, without limitation, including the Asset Purchase Agreement, the termination of the Patent Cross-License Agreement, the acquisition of the patents from Butamax, Gevo’s control over patents for the production of renewable isobutanol, the benefits of the acquisition of patents, the IP evaluation performed by Peak Value IP, LLC, Gevo’s ability to monetize any patents, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Investor and Media Contact

+1 720-647-9605

IR@gevo.com

Capstone Green Energy (NASDAQ:CGRN) Receives Two Orders for Innovative Carbon-Neutral Renewable Energy Systems

Posted on by Admin

 


Capstone Green Energy (NASDAQ:CGRN) Receives Two Orders for Innovative Carbon-Neutral Renewable Energy Systems

 

New Systems will Supply Cost-Effective, Clean Generating Power Using Innovative Biomass Fuels to Provide a Carbon-Neutral Solution

VAN NUYS, CA / ACCESSWIRE / September 23, 2021 / Capstone Green Energy Corporation (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN), a global leader in carbon reduction and on-site resilient green energy solutions, announced today that it has received two orders for externally fired microturbines through its global energy conversion partner, Professor Dr. Berg & Kießling GmbH (B+K) as the generating component within the company’s innovative ClinX system.

The first ClinX system is for a metal processing plant in Brandenburg, Germany. The externally fired Capstone C65 will be part of a Combined Heat and Power (CHP) system that is expected to provide 80% of the facility’s electrical demand, and when adding energy storage, the system should meet all the electric demands of the facility. The system should also provide 100% of the heat required for the drying chambers used in the coating process. Fueled by wood chips sustainably harvested from surrounding forests, this renewable energy system will be completely carbon-neutral, helping the customer achieve its green energy goals.

The second system is part of an upgrade to an existing system currently installed at a municipal utility in Hessen, Germany. The upgraded CHP system will feature a Capstone C200 and use a variety of waste products (heterogeneous biomass) as a fuel by way of a pyrolysis process. Not only should the self-sufficient energy system generate 100% of the facility’s electricity, but it will also provide heat energy for the drying process that prepares the pyrolysis materials. Any unused waste heat can be converted into a higher-quality energy source of electricity.

Both systems are expected to be commissioned in early 2022.

“In the case of the metal processing plant, the shift to 100% renewable energy will have benefits beyond cost savings and energy efficiency, including expanding the company’s ability to bid on projects that have strict environmental requirements,” said Sebastian Kießling, Executive Partner at B+K. “For the municipal utility, the use of post-combustion power generation using an externally-fired microturbine will significantly improve the economics of the project.”

“Clearly, there are enormous upsides to carbon-neutral projects like these, and new partners like B+K are critical to the expanded solutions-based business model we launched on Earth Day earlier this year,” said Darren Jamison, President and Chief Executive Officer of Capstone Green Energy. “Whether we’re talking about leveraging sustainable and renewable sources, waste byproducts, or hydrogen, fuel flexibility has always been at the very heart of our innovative microturbine technology. We’re excited that these projects demonstrate to other entities and businesses that the path to a green energy future can and does align with their financial goals.”

About Capstone Green Energy

Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Conversion Products are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Products business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen Energy Solutions, Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@CGRNenergy.com. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three years are estimated at 1,115,100 tons of carbon and $698 million in annual energy savings.

For more information about the Company, please visit: www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on Twitter, LinkedIn, Instagram, Facebook, and YouTube.

Cautionary Note Regarding Forward-Looking Statements

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
ir@CGRNenergy.com

SOURCE: Capstone Green Energy Corporation

QuickChek – September 23, 2021

Posted on by Admin



Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors

Ayala Pharmaceuticals announced the publication of two case studies of adult patients with desmoid tumors treated with AL101

Research, News & Market Data on Ayala

Watch recent presentation from Ayala



CanAlaska Deals Three Uranium Projects in the Athabasca Basin

CanAlaska Uranium announced it has entered into a Letter of Intent with Terra Uranium Pty Ltd, an Australian private limited corporation

Research, News & Market Data on CanAlaska

Watch recent presentation from CanAlaska



CoreCivic Announces Upsizing and Pricing of Tack-On Offering of $225 Million 8.25% Senior Notes Due 2026

CoreCivic announced that it successfully upsized and priced its offering

See today’s research report from Joe Gomes, Senior Research Analyst at Noble Capital Markets

Research, News & Market Data on CoreCivic

Watch recent presentation from CoreCivic



Gevo Acquires Butamax Patent Estate

Gevo announced that it has entered into an asset purchase agreement with Butamax Advanced Biofuels and its affiliate, Danisco US to acquire certain patents

Research, News & Market Data on Gevo

Watch recent presentation from Gevo



Capstone Green Energy (NASDAQ:CGRN) Receives Two Orders for Innovative Carbon-Neutral Renewable Energy Systems

Capstone Green Energy announced that it has received two orders for externally fired microturbines through its global energy conversion partner, Professor Dr. Berg & Kießling GmbH

Research, News & Market Data on Capstone Green Energy

Watch recent presentation from Capstone Green Energy

 

Stay up to date. Follow us:

 

CoreCivic, Inc. (CXW) – Title 42 Ruling Contract Updates

Posted on by Admin

Thursday, September 23, 2021

CoreCivic, Inc. (CXW)
Title 42 Ruling; Contract Updates

CoreCivic is a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through corrections and detention management, a growing network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. We are a publicly traded real estate investment trust and the nation’s largest owner of partnership correctional, detention and residential reentry facilities. We also believe we are the largest private owner of real estate used by U.S. government agencies. The Company has been a flexible and dependable partner for government for more than 35 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Title 42 Ruling. Last week U.S. District Judge Emmet Sullivan blocked the Federal government from expelling migrant families from the United States under “Title 42.” The order takes effect in 14 days. The government has filed a notice of appeal to the United States Court of Appeals for the District of Columbia Circuit. If upheld, the elimination of Title 42 expulsions could increase demand for CoreCivic beds.

    Key Points.  In a 58-page ruling, Judge Sullivan found that the Title 42 policy does not authorize the expulsion of migrants and therefore does not allow for those removed to be denied the opportunity to seek asylum in the U.S. While the ruling applies to families, many of whom are already being allowed to stay in the U.S., if Title 42 does not authorize the expulsion of families one can see the …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Orion Group Holdings Inc. Announces Contract Awards of Approximately $35 Million

Posted on by Admin

 


Orion Group Holdings, Inc. Announces Contract Awards of Approximately $35 Million

 

HOUSTON–(BUSINESS WIRE)–Sep. 22, 2021– 
Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”) a leading specialty construction company, today announced contract awards totaling approximately 
$35 million.

The Company’s Marine segment has been awarded four contracts valued at a combined 
$35 million to perform marine and infrastructure construction work in the gulf coast, as well as in 
Alaska.

In the gulf coast, the Company has been awarded three contracts to construct marine infrastructure for private sector clients in 
Texas and 
Louisiana. Two of these awards, valued at 
$11.8 million and 
$6.7 million, are in the greater 
Houston area and call for the construction and dredging of new ship and barge berths for petrochemical loading and unloading. The third project, valued at approximately 
$9 million, calls for the replacement of an existing barge dock at a terminal located west of 
New Orleans. Work on all three projects is expected to commence in the fourth quarter of 2021 and be complete by third quarter of 2022.

In addition, the Company has been awarded a contract from the 
US Department of Transportation to demolish and replace an existing bridge in Alaska’s 
Denali National Park. This project is valued at 
$7.8 million and will commence late in the first quarter of 2022 with the work completed in late 2023.

“We’re pleased to announce these project awards, particularly those in the private sector energy and industrial spaces,” said  Mark Stauffer, Orion’s President and Chief Executive Officer. “Our disciplined approach to bidding project opportunities is paying off, and we expect to see significant additional awards in our marine business in the coming weeks.”

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental 
United States, 
Alaska, 
Canada and the 
Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in 
Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on 
March 2, 2021, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Orion Group Holdings Inc.
Francis Okoniewski, Vice President Investor Relations
(346) 616-4138
fokoniewski@orn.net
www.oriongroupholdingsinc.com

Robert Tabb, Executive Vice President & CFO
(713) 852-6500
www.oriongroupholdingsinc.com

Source: 
Orion Group Holdings, Inc.

QuickChek – September 22, 2021

Posted on by Admin



Comstock Commences Production At Mercury And Gold Extraction Facility

Comstock Mining announced that Clean Mercury Remediation Technologies, MCU’s Philippine Inc.’s joint venture, has received its remaining permit and commenced full operations

Research, News & Market Data on Comstock

Watch recent presentation from Comstock



Orion Group Holdings, Inc. Announces Contract Awards

Orion announced contract awards totaling approximately $35 million

Orion announced contract awards totaling approximately $26 million

Research, News & Market Data on Orion

Watch recent presentation from Orion



CoreCivic Announces Proposed Tack-On Offering of $100 Million of 8.25% Senior Notes Due 2026

CoreCivic announced that it intends to offer an additional $100,000,000 aggregate principal amount of its 8.25% senior unsecured notes due 2026

Research, News & Market Data on CoreCivic

Watch recent presentation from CoreCivic



Aurania Announces a Change to its Board of Directors

Aurania Resources announced that Mr. Alfred Lenarciak has resigned from its board of directors for personal reasons, effective immediately

Research, News & Market Data on Aurania

Watch recent presentation from Aurania



Onconova Therapeutics Announces Encouraging Clinical Data Supporting The Anti-Cancer Activity Of Rigosertib-Nivolumab Combination In Advanced KRAS+ Non-Small Cell Lung Cancer

Onconova Therapeutics announced preliminary safety and efficacy data from an investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune checkpoint inhibitor nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC)

Research, News & Market Data on Onconova

Watch recent presentation from Onconova

 

Stay up to date. Follow us:

 

Onconova Therapeutics Announces Encouraging Clinical Data Supporting The Anti-Cancer Activity Of Rigosertib-Nivolumab Combination In Advanced KRAS+ Non-Small Cell Lung Cancer

Posted on by Admin


Onconova Therapeutics Announces Encouraging Clinical Data Supporting The Anti-Cancer Activity Of Rigosertib-Nivolumab Combination In Advanced KRAS+ Non-Small Cell Lung Cancer

 

Preliminary Phase 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7 evaluable patients

Responses were seen in patients with different KRAS mutations

Data supports further development of rigosertib, in combination with immune checkpoint inhibitors in KRAS mutated (KRAS+) non-small cell lung cancer

Management hosting webinar with key opinion leaders to discuss data today at 4:30 p.m. ET

NEWTOWN, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preliminary safety and efficacy data from an investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune checkpoint inhibitor nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC). The data, which are being featured in a presentation at the 3rd Annual RAS Targeted Drug Development Summit, support the potential anti-cancer activity of rigosertib-nivolumab combination therapy in this indication and show that the doublet has been well tolerated to-date. Three quarters of patients enrolled in the trial have failed two or more lines of prior therapy and all have failed immune checkpoint inhibitors in various combinations.

Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, commented, “The data being presented today support the potential applicability of rigosertib’s mechanism of action against multiple KRAS mutations and its synergy with immuno-oncology therapeutics. Radiographic responses were seen across multiple KRAS variants, which potentially differentiates rigosertib from other RAS pathway modulators that target particular KRAS mutations. These responses were observed at the primary tumor site as well as metastatic sites such as the pleura and bone. These results also suggest that rigosertib may augment the response to checkpoint inhibitors, which is consistent with observations from preclinical studies, with potential applicability to indications such as NSCLC, melanoma, and others. Looking forward, we will continue to leverage our investigator-initiated study program to advance rigosertib’s clinical development in high-need KRAS mutated indications while keeping our primary focus on our lead ON 123300 (narazaciclib) program.”

Key data from the presentation include:

Demographics:

  • All enrolled patients (12/12) failed at least one line of prior therapy with a PD-1 checkpoint inhibitor (includes evaluable and non-evaluable patients)
  • 9 of 12 (75%) enrolled patients failed at least two prior lines of therapy

Response Results:

  • 2 of 7 (29%) evaluable patients achieved a partial response (PR)
    • PRs were observed in patients with two distinct KRAS mutations (G12C, G12V)
  • 3 of 7 (43%) evaluable patients achieved disease control (PR or stable disease)
  • 4 of 7 (57%) evaluable patients experienced progressive disease

Adverse Event Results:

  • The combination of rigosertib and nivolumab has been well tolerated and the maximum tolerated dose has not been reached to-date. Treatment related adverse events were mostly mild with two grade 3 adverse events.
  • 3 patients discontinued study drug (2 grade 2 genitourinary toxicities, 1 dose limiting grade 3 hyponatremia)
  • No unexpected safety events or synergistic toxicities have been observed

“Combining rigosertib with the immune checkpoint inhibitor nivolumab has been well tolerated and notably led to partial responses in 29% of evaluable patients who had previously progressed on prior checkpoint inhibitor therapies,” said Rajwanth Veluswamy, M.D., Assistant Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai and Principal Investigator of the trial. “This safety and early efficacy signal highlights the combination of rigosertib and nivolumab’s ability to target KRAS mutated NSCLCs and potentially overcome immune checkpoint inhibitor resistance mechanisms. Importantly, responses were seen with different KRAS+ variants, addressing a critical unmet need.”

Mark S. Gelder, M.D., Chief Medical Officer of Onconova, commented, “We look forward to the continuation of this study and to continue development of the rigosertib nivolumab combination as a potential treatment for patients with limited therapeutic options.”

Slides from the presentation titled, “Phase 1/2 Trial of Rigosertib & Nivolumab in KRAS-Mutated NSCLC in 2nd+ Line” will be available on the “Scientific Presentations” section of the Onconova website following the conference.

Webinar Featuring Expert Overview from Key Opinion Leaders
Onconova will host a webinar today, September 22, 2021, at 4:30 p.m. ET to discuss the preliminary Phase 1/2a data. The call will feature expert discussion with Dr. Veluswamy and Scott Antonia, M.D., Ph.D., Professor of Medicine at the Duke Cancer Institute and Director of its Center for Cancer Immunotherapy. A question and answer session with these experts will follow formal presentations by Dr. Veluswamy and members of the Onconova management team.

To attend the webinar, click here. A replay of the webinar will be available by visiting the investors and media page on Onconova’s website at www.onconova.com and clicking on the webcast link.

About the Investigator-initiated Phase 1/2a Trial
This Phase 1/2a trial is designed to evaluate the combination of rigosertib and nivolumab in advanced KRAS+ metastatic NSCLC patients who have progressed on standard of care with anti-PD-1 monotherapy or anti-PD-1 in combination with chemotherapy. It includes a dose-escalating Phase 1 portion followed by a Phase 2a dose-expansion portion. Patients in the trial receive oral rigosertib twice daily on days 1-21, and intravenous nivolumab on days 1 and 15 of 28-day cycles. The primary endpoints of the trial are safety assessments to determine maximum tolerated dose and overall response rate. Secondary endpoints include progression free survival and overall survival. For more information on the trial, see ClinicalTrials.gov Identifier: NCT04263090.

About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1/2a investigator-initiated study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the timing of Onconova’s and investigator-initiated clinical development and data presentation plans, and the mechanisms and indications for Onconova’s product candidates. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “preliminary,” “encouraging,” “approximately” or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova’s clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova’s collaborations, market conditions and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com 

Endeavour Silver (EXK)(EDR:CA) – Improved Economics of the Proposed Terronera Mine Enhance the Longer-Term Outlook

Posted on by Admin

Wednesday, September 22, 2021

Endeavour Silver (EXK)(EDR:CA)
Improved Economics of the Proposed Terronera Mine Enhance the Longer-Term Outlook

As of April 24, 2020, Noble Capital Markets research on Endeavour Silver is published under ticker symbols (EXK and EDR:CA). The price target is in USD and based on ticker symbol EXK. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Endeavour Silver Corp is a precious metal mining company. The company is primarily engaged in silver mining and owns three high-grade, underground, silver-gold mines in Mexico. Its other business activities include acquisition, exploration, development, extraction, processing, refining and reclamation. The company is organized into four operating mining segments, Guanacevi, Bolanitos, El Cubo, and El Compas, which are located in Mexico as well as Exploration and Corporate segments. Its Exploration segment consists of projects in the exploration and evaluation phases in Mexico and Chile.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Updating estimates. While our EPS estimates are unchanged, we have trimmed our 2021 EBITDA forecast to $45.4 million from $47.5 million based on modestly lower silver and gold prices. For 2022, we have increased our EPS and EBITDA estimate to $0.20 and $79.2 million from $0.18 and $75.5 million, respectively, based on an improved operating cost structure.

    Terronera feasibility study.  Endeavour recently reported the results of a feasibility study for Terronera which is expected to become Endeavour’s largest and lowest cost mine. Over a 12-year mine life, Terronera is expected to produce an average of 3.3 million and 33 thousand ounces of silver and gold per year, respectively. Initial capital expenditures are expected to be $175 million. For …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Virtual Roadshow with One Stop Systems (OSS) CEO David Raun and CFO John Morrison

Posted on by Admin

One Stop Systems CEO David Raun makes a formal corporate presentation. Afterwards, he is joined by CFO John Morrison and Noble Capital Markets Senior Research Analyst Joe Gomes for a Q & A session.

Research, News, and Advanced Market Data on OSS


Information on upcoming live virtual roadshows


One Stop Systems, Inc. (OSS) designs and manufactures innovative AI Transportable edge computing modules and systems, including ruggedized servers, compute accelerators, expansion systems, flash storage arrays and Ion Accelerator™ SAN, NAS and data recording software for AI workflows. These products are used for AI data set capture, training, and large-scale inference in the defense, oil and gas, mining, autonomous vehicles and rugged entertainment applications.

OSS utilizes the power of PCI Express, the latest GPU accelerators and NVMe storage to build award-winning systems, including many industry firsts, for industrial OEMs and government customers. The company enables AI on the Fly® by bringing AI datacenter performance to ‘the edge’, especially on mobile platforms, and by addressing the entire AI workflow, from high-speed data acquisition to deep learning, training and inference. OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com.

Release – Orion Group Holdings Inc. Announces Contract Awards of Approximately $26 Million

Posted on by Admin

 


Orion Group Holdings, Inc. Announces Contract Awards of Approximately $26 Million

 

HOUSTON–(BUSINESS WIRE)–Sep. 22, 2021– 
Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”) a leading specialty construction company, today announced six contract awards in its key markets for its Concrete segment totaling approximately 
$26 million.

The Company was recently awarded two contracts in the 
Houston, Texas, area including an 
$8 million contract for the construction of a building as part of a new industrial park and a 
$9 million contract for the construction of four tilt-wall buildings in a new distribution center. Both projects are expected to commence construction in the fourth quarter of 2021 and be completed before year end 2022.

The Company also has been awarded a contract valued at 
$3.2 million to construct three buildings for a new school in its 
Dallas market and two contracts valued at over 
$4 million to build new townhome facilities in 
Austin, Texas. All three projects are expected to begin construction during the fourth quarter of 2021 and be completed in the second quarter of 2022.

In addition, the Company was awarded a 
$2.1 million contract to construct a single-story tilt-wall building with associated site work in Daytona, 
Florida, marking the first project for the Company’s Concrete segment outside of 
Texas. The project is expected to begin in the fourth quarter of 2021 and be complete by the end of the first quarter of 2022.

“The capture of work in 
Florida is of significant importance as it represents a key first step in our strategic plan to expand our Concrete business to this market,” said  Mark Stauffer, Orion’s President and Chief Executive Officer. “Our Marine segment has had an active present in the 
Florida market since the 1940s and our Concrete teams will leverage our existing experience, relationships and resources to grow into this market.”

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental 
United States, 
Alaska, 
Canada and the 
Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in 
Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on 
March 2, 2021, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Orion Group Holdings Inc.
Francis Okoniewski, Vice President Investor Relations
(346) 616-4138
fokoniewski@orn.net
www.oriongroupholdingsinc.com

Robert Tabb, Executive Vice President & CFO
(713) 852-6500
www.oriongroupholdingsinc.com

Source: 
Orion Group Holdings, Inc.

Release – Onconova Therapeutics Announces Encouraging Clinical Data Supporting The Anti-Cancer Activity Of Rigosertib-Nivolumab Combination

Posted on by Admin


Onconova Therapeutics Announces Encouraging Clinical Data Supporting The Anti-Cancer Activity Of Rigosertib-Nivolumab Combination In Advanced KRAS+ Non-Small Cell Lung Cancer

 

Preliminary Phase 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7 evaluable patients

Responses were seen in patients with different KRAS mutations

Data supports further development of rigosertib, in combination with immune checkpoint inhibitors in KRAS mutated (KRAS+) non-small cell lung cancer

Management hosting webinar with key opinion leaders to discuss data today at 4:30 p.m. ET

NEWTOWN, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preliminary safety and efficacy data from an investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune checkpoint inhibitor nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC). The data, which are being featured in a presentation at the 3rd Annual RAS Targeted Drug Development Summit, support the potential anti-cancer activity of rigosertib-nivolumab combination therapy in this indication and show that the doublet has been well tolerated to-date. Three quarters of patients enrolled in the trial have failed two or more lines of prior therapy and all have failed immune checkpoint inhibitors in various combinations.

Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, commented, “The data being presented today support the potential applicability of rigosertib’s mechanism of action against multiple KRAS mutations and its synergy with immuno-oncology therapeutics. Radiographic responses were seen across multiple KRAS variants, which potentially differentiates rigosertib from other RAS pathway modulators that target particular KRAS mutations. These responses were observed at the primary tumor site as well as metastatic sites such as the pleura and bone. These results also suggest that rigosertib may augment the response to checkpoint inhibitors, which is consistent with observations from preclinical studies, with potential applicability to indications such as NSCLC, melanoma, and others. Looking forward, we will continue to leverage our investigator-initiated study program to advance rigosertib’s clinical development in high-need KRAS mutated indications while keeping our primary focus on our lead ON 123300 (narazaciclib) program.”

Key data from the presentation include:

Demographics:

  • All enrolled patients (12/12) failed at least one line of prior therapy with a PD-1 checkpoint inhibitor (includes evaluable and non-evaluable patients)
  • 9 of 12 (75%) enrolled patients failed at least two prior lines of therapy

Response Results:

  • 2 of 7 (29%) evaluable patients achieved a partial response (PR)
    • PRs were observed in patients with two distinct KRAS mutations (G12C, G12V)
  • 3 of 7 (43%) evaluable patients achieved disease control (PR or stable disease)
  • 4 of 7 (57%) evaluable patients experienced progressive disease

Adverse Event Results:

  • The combination of rigosertib and nivolumab has been well tolerated and the maximum tolerated dose has not been reached to-date. Treatment related adverse events were mostly mild with two grade 3 adverse events.
  • 3 patients discontinued study drug (2 grade 2 genitourinary toxicities, 1 dose limiting grade 3 hyponatremia)
  • No unexpected safety events or synergistic toxicities have been observed

“Combining rigosertib with the immune checkpoint inhibitor nivolumab has been well tolerated and notably led to partial responses in 29% of evaluable patients who had previously progressed on prior checkpoint inhibitor therapies,” said Rajwanth Veluswamy, M.D., Assistant Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai and Principal Investigator of the trial. “This safety and early efficacy signal highlights the combination of rigosertib and nivolumab’s ability to target KRAS mutated NSCLCs and potentially overcome immune checkpoint inhibitor resistance mechanisms. Importantly, responses were seen with different KRAS+ variants, addressing a critical unmet need.”

Mark S. Gelder, M.D., Chief Medical Officer of Onconova, commented, “We look forward to the continuation of this study and to continue development of the rigosertib nivolumab combination as a potential treatment for patients with limited therapeutic options.”

Slides from the presentation titled, “Phase 1/2 Trial of Rigosertib & Nivolumab in KRAS-Mutated NSCLC in 2nd+ Line” will be available on the “Scientific Presentations” section of the Onconova website following the conference.

Webinar Featuring Expert Overview from Key Opinion Leaders
Onconova will host a webinar today, September 22, 2021, at 4:30 p.m. ET to discuss the preliminary Phase 1/2a data. The call will feature expert discussion with Dr. Veluswamy and Scott Antonia, M.D., Ph.D., Professor of Medicine at the Duke Cancer Institute and Director of its Center for Cancer Immunotherapy. A question and answer session with these experts will follow formal presentations by Dr. Veluswamy and members of the Onconova management team.

To attend the webinar, click here. A replay of the webinar will be available by visiting the investors and media page on Onconova’s website at www.onconova.com and clicking on the webcast link.

About the Investigator-initiated Phase 1/2a Trial
This Phase 1/2a trial is designed to evaluate the combination of rigosertib and nivolumab in advanced KRAS+ metastatic NSCLC patients who have progressed on standard of care with anti-PD-1 monotherapy or anti-PD-1 in combination with chemotherapy. It includes a dose-escalating Phase 1 portion followed by a Phase 2a dose-expansion portion. Patients in the trial receive oral rigosertib twice daily on days 1-21, and intravenous nivolumab on days 1 and 15 of 28-day cycles. The primary endpoints of the trial are safety assessments to determine maximum tolerated dose and overall response rate. Secondary endpoints include progression free survival and overall survival. For more information on the trial, see ClinicalTrials.gov Identifier: NCT04263090.

About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1/2a investigator-initiated study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the timing of Onconova’s and investigator-initiated clinical development and data presentation plans, and the mechanisms and indications for Onconova’s product candidates. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “preliminary,” “encouraging,” “approximately” or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova’s clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova’s collaborations, market conditions and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com 

Facebook’s Practice of Whitelisting Accounts is Being Reviewed

Posted on by Admin

Facebook’s “Supreme Court” to Rule on Favoritism of Elite Users

 

Should Facebook have different rules for high-profile users than it does for the masses? Facebook’s Oversight Board said this week that it will review the company’s use of more relaxed content rules for high-profile users such as athletes and politicians. Under review is the companies “Cross Check” program for the better-known users.

 

What
is the Oversight Board

Mark Zuckerberg, the founder and CEO of Facebook appointed an Oversight Board in 2019. It’s a worldwide 20-member body, which includes human rights activists, lawyers, journalists, professors, and others to serve as an entity to hear appeals after Facebook makes decisions on content moderation. It is sometimes referred to as “Facebook’s Supreme Court” as it can overturn decisions made by company executives – it has the final word.

Since its creation, the Oversight Board has received more than 500,000 requests from Facebook users to examine its content moderation decisions. It has issued 15 decisions in what it calls “important cases,” with 11 of those decisions overturning Facebook. 

 

What’s at Stake in this Review

The review comes after a series of investigative reports by The Wall Street Journal that included a description of how the social media platform Facebook has applied one set of content moderation rules to regular users, but allowed high-profile users significantly more latitude with material that potentially violates Facebook’s content guidelines. It is to include how politicians, celebrities, journalists, etc. may be given different treatment or allowed another standard of conduct.

 

Source: oversightboard.com

 

The Wall Street Journal report showed the “cross-check” program effectively shields millions of accounts from the enforcement actions that more common Facebook users are held to. The program has allowed “whitelisted” accounts to post false claims that would not otherwise be tolerated. It also has allowed harassment, and other issues, according to the Journal.

Last year there were almost six million accounts in the system getting special treatment by Facebook employees. For the rest of Facebook’s 2.8 billion monthly visitors, violating the company’s guidelines against issues like bullying or hate speech is handled by automated systems. The Oversight Board said this week that Facebook must be more transparent in how rules are applied.

What Happens Next?

The Board said it expects to be briefed by Facebook within the next few days. The findings and any action will be published in October as part of its quarterly transparency report. The Board also said it has been examining the cross-check system “for some time.” In the past, it warned that a lack of transparency “could contribute to perceptions that Facebook is unduly influenced by political and commercial considerations.”

 

Take-Away

The Oversight Board is a Facebook-funded body that operates outside of the company’s formal corporate chain of command, it arbitrates decisions about content moderation. It’s in place as a separate entity outside of Facebook that has the final say in decision-making on moderation. It is currently looking at a practice Facebook uses, which uses digital electronic moderating for some and a far less stringent moderation system for others.

As with most businesses, reputation is important. The Board created less than two years by Mark Zuckerberg is to help protect the reputation of the company. The outcome of this review will be known in October.

 

Suggested Reading:



Advertising Rules Becoming a Guessing Game on Some Social Media

Your Data is Being Used to Generate Big Returns





Seeking Alpha Paywall Causes Frustration

Digital Media and Entertainment Industry Outlook

 

Sources:

https://oversightboard.com/news/3056753157930994-to-treat-users-fairly-facebook-must-commit-to-transparency/

https://www.cbsnews.com/news/facebook-cross-xcheck-oversight-board/

https://oversightboard.com/

https://www.wsj.com/articles/facebook-files-xcheck-zuckerberg-elite-rules-11631541353

 

Stay up to date. Follow us:

 

Release – Comstock Commences Production At Mercury And Gold Extraction Facility

Posted on by Admin


Comstock Commences Production At Mercury And Gold Extraction Facility

 

VIRGINIA CITY, NEVADA, September 22, 2021 – Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) and Mercury Clean Up LLC (“MCU”) today announced that Clean Mercury Remediation Technologies (“CMRT”), MCU’s Philippine Inc.’s joint venture, has received its remaining permit and commenced full operations in the venture’s first commercial mercury remediation system in the province of Davao D’ Oro, Philippines.

“We are pleased to restart and initiate sales as we remediate mercury contamination and return the local environment back to its natural state,” said Comstock’s Executive Chairman and Chief Executive Officer, Corrado DeGasperis.

Artisanal and Small Scale Gold Mining (ASGM)

Mercury?dependent ASGM uses a process known as amalgamation to dissolve gold from natural deposits. The amalgam is then typically isolated by hand and then heated to distill the mercury and isolate the gold. Problematically, mercury is hazardous to human health and the environment, where residual ASGM wastes contaminate water and soil and bioaccumulate into the food chains. The risks to children are also substantial, with mercury emissions from ASGM resulting in both physical and mental disabilities and compromised development. The amalgamation process was regulated into extinction by most countries, but upwards of 20 million people in more than 70 countries still use mercury to mine for gold, making mercury pollution a U.N. prioritized global issue through the Minamata Convention.

Proprietary Remediation and Extraction Process

The Naboc River in Davao D’ Oro has long been a channel for effluents of mining activities, with hundreds of historical mining operations without sufficient tailing ponds to prevent releases of toxic, mercury-laden discharges. That history is evidenced by high levels of mercury and other contaminants in the local ecosystem, according to the Philippine’s Department of Environment and Natural Resources (DENR).

MCU’s Davao D’Oro facility is designed to remediate mercury contamination from the entire local ecosystem, thereby reviving a 24 kilometer stretch of the Naboc River and restoring all of its downstream irrigation systems for safe use, while extracting and selling residual gold and cleaned sand, soil and gravel co-products for multiple high-margin revenue streams.

“The Davao D’Oro facility is expected to produce pre-tax operating income, depending on yields,” continued DeGasperis. “Our deployment plans for MCU involve sustained growth through continued expansion with many additional facilities after moving into positive cash flows with the Davao D’Oro facility over the next few months.”

A photo accompanying this announcement is available here.

About Comstock Mining Inc.

Comstock Mining Inc. (NYSE: LODE) (the “Company”) is an emerging innovator and leader in the sustainable extraction, valorization, and production of scarce natural resources, with a focus on high value strategic materials that are essential to meeting the rapidly increasing global demand for clean energy, carbon-neutrality, and natural products. To learn more, please visit www.comstockmining.com.

Forward-Looking Statements

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so.

Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future prices and sales of, and demand for, our products; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; and future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, taxes, earnings and growth. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, mercury remediation and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration or mercury remediation, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with mercury remediation, metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; ability to achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology, mercury remediation technology and efficacy, quantum computing and advanced materials development, and development of cellulosic technology in bio-fuels and related carbon-based material production; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

Contact Information    
Comstock Mining Inc.

P.O. Box 1118

Virginia City, NV 89440

www.comstockmining.com

 Corrado De Gasperis

Executive Chairman & CEO

Tel (775) 847-4755

degasperis@comstockmining.com

 Zach Spencer

Director of External Relations

Tel (775) 847-5272 Ext.151

questions@comstockmining.com